Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
213
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Remegen
•
08 Nov 2020 09:57
A Different Angle - RemeGen Vs Akeso (Insights on Valuation)
In this article, by comparing RemeGen and Akeso's pipelines from different aspects to provide referable and helpful insights about the valuation...
Xinyao (Criss) Wang
Follow
347 Views
Share
bullish
•
Antengene
•
06 Nov 2020 07:40
Antengene: Gunning To Move Up in Line
This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...
Kemp Dolliver, CFA
456 Views
Share
bullish
•
Ant Group
•
29 Oct 2020 09:36
Ant Group IPO: STAR Market Trading Stats, A/H Spread
Ant Group aims to raise around USD 35bn via a dual listing on HKEX and STAR board. In this note, we will look at past STAR market IPOs, their...
Zhen Zhou, Toh
349 Views
Share
bullish
•
Everest Medicines
•
24 Oct 2020 23:47
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
Kemp Dolliver, CFA
332 Views
Share
bearish
•
Evergrande Auto
•
28 Sep 2020 16:36
Evergrande Auto (708 HK): EGM Ahead Of Star Market Listing
This week in StubWorld ... Three days after raising HK$4bn via a top-up placement, Evergrande Auto (708 HK) ("EA") also officially known...
David Blennerhassett
Follow
288 Views
Share
First
Previous
33
34
35
36
37
38
39
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x